Welcome to our dedicated page for Gohealth SEC filings (Ticker: GOCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoHealth, Inc. filings document the public-company record for a Medicare-focused digital health and insurance marketplace. Its 8-K reports cover operating results, financial-condition updates, capital and credit arrangements, and material agreements, including secured term-loan financing involving GoHealth subsidiaries such as Norvax, LLC.
Proxy and governance filings describe annual meeting proposals, director elections, executive compensation votes, incentive-plan matters, auditor ratification, board appointments, committee roles, and stockholder voting results. The filing record also includes capital-structure disclosures, risk and liquidity context tied to Medicare Advantage conditions, and Nasdaq continued-listing compliance notices for GOCO common stock.
GoHealth (Nasdaq: GOCO) filed an 8-K disclosing the results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
Shareholders elected three Class II directors—Brandon M. Cruz (17,218,021 FOR), Alan Wheatley (17,932,740 FOR) and Abhiraj R. Modi (17,619,537 FOR)—to serve until the 2028 meeting. Ernst & Young LLP was ratified as independent auditor with 21,544,738 FOR and only 557,922 AGAINST. The non-binding say-on-pay resolution passed (17,026,293 FOR; 992,227 AGAINST), and shareholders approved an amendment to the 2020 Incentive Award Plan (16,755,619 FOR; 1,287,341 AGAINST).
No financial performance metrics, strategic updates, or other material events were included in the filing.